Renalytix appoints Howard Doran as Chief Business Officer to lead KidneyIntelX sales

Renalytix plc

Howard Doran appointed Chief Business Officer effective Sept 1, 2023, to lead KidneyIntelX global sales.
Doran brings 30+ yrs diagnostics exp; served as CEO of LipoScience (acquired by LabCorp) and President of Hologic Global Diagnostics.
Annual base salary of $300,000; target bonus 60% of base; options for 300,000 ordinary shares with 3-yr vesting and 1-yr cliff.
Renalytix commercializes FDA-approved AI prognostic blood test for type 2 diabetes and chronic kidney disease.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Howard Doran Jr.

Chief Business Officer

RNLXY · Renalytix plc

Effective: 2023-09-01
Filed: September 8, 2023, 7:59 PM ET

On September 1, 2023, the Company’s Board of Directors appointed Howard Doran Jr. as the Company’s Chief Business Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Howard Doran Jr. was appointed as Chief Business Officer at Renalytix plc.

Action: appointed
Role: Chief Business Officer

Exact text from the filing

On September 1, 2023, the Company’s Board of Directors appointed Howard Doran Jr. as the Company’s Chief Business Officer.

View on SEC.gov

Renalytix plc filing history →

Source: SEC EDGAR

accession 0000950170-23-047260

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.